Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Kempower Q4’24: Towards normalization

Kempower

The main feature of the Q4 figures was the normalization of order intake after weak Q1-Q3. Revenue was also slightly better than expected. High customer inventory levels continue to impact demand in Europe, but evidence of a recovery in the demand outlook strengthens the risk/reward ratio. Analyst Pauli Lohi summarizes.

Läs senaste analysen här

Följ oss på:

  • X (Twitter)
  • Instagram
  • TikTok

Du är hjärtligt välkommen att ansluta dig till vår kostnadsfria community och delta i heta aktiediskussioner på forumet. 

Stay up to date
Analyst Interviews

Recent videos

Herantis Pharma as an Investment | Life Science Night Dec 9, 2025
2025-12-09 22:11 Herantis Pharma
Aiforia as an Investment | Life Science Night Dec 9, 2025
2025-12-09 22:10 Aiforia Technologies
Orion as an Investment | Life Science Night Dec. 9, 2025
2025-12-09 22:10 Orion
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
2025-12-09 22:09 Aiforia Technologies
Life Science Night | December 9, 2025
2025-12-09 14:30 Orion
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.